TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Patients With Extensive-Stage SCLC
Source: Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Extensive-Stage SCLC
Treatment options for patients with extensive-stage disease (ED) small cell lung cancer (SCLC) include:
Source links and citations
Immune checkpoint modulation and combination chemotherapy.
Source links and citations
Immune checkpoint modulation and combination chemotherapy.
Atezolizumab.
Source links and citations
Immune checkpoint modulation and combination chemotherapy.
Durvalumab.
Source links and citations
Combination chemotherapy.
Source links and citations
Radiation therapy.
Source links and citations
Radiation therapy.
Thoracic radiation therapy for patients who respond to chemotherapy.
Source links and citations
Radiation therapy.
Prophylactic cranial irradiation (PCI).
Source links and citations
Clinical trials evaluating new drug regimens or alternative drug doses and schedules.
Continue within this section
Preserved source evidence · Not medical advice